BloodThinnerHelp.com reports on a lawsuit filed in Vermont against the manufacturers of blood-thinning drug Xarelto: Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson). This particular complaint was filed under case number 2:14-cv-00159-CR in a Vermont federal court by a young woman whose father died from uncontrollable bleeding complications. The lawsuit alleges that anticoagulant Xarelto caused the man’s uncontrollable bleeding and death.
The daughter’s complaint details that her father was prescribed Xarelto in an attempt to treat his atrial fibrillation. This is a fairly common heart condition which often makes the heart beat at a faster rate than normal. Atrial fibrillation can cause blood clots or strokes, so individuals diagnosed with the condition commonly use blood thinners as a preventative measure.
After using Xarelto for just a short time, the plaintiff’s father injured himself and began to bleed. He was rushed to the hospital, where doctors said he had suffered a parenchymal hemorrhage. Due to the active Xarelto in his system, the doctors were unable to control the man’s blood loss or get his blood to clot. They exhausted every attempt to keep him alive, which they were able to do for 6 days before he ultimately passed away.
Lack of antidote for the drug
Due to these circumstances, the daughter’s complaint directly addresses what many other Xarelto lawsuits do: the lack of antidote for the drug. Because Xarelto has no antidote, patients using the drug who begin to bleed have few options. In these circumstances, physicians simply cannot clot the blood, so they have to resort to extreme life saving measures such as surgeries to remove blood pools, or blood transfusions to replace lost blood.
Patients who use traditional blood thinners do not encounter these same issues. Traditional blood thinners have an antidote available in vitamin K. This means that when someone with a traditional blood thinner in their system begins to bleed, physicians can treat them with vitamin K, and this will counter the effects of the drug and allow their blood to clot.
In her complaint, the daughter states that had she and her father been previously aware of these dangerous factors concerning Xarelto, they would have chosen a safer alternative. Many plaintiffs involved in the current Xarelto litigation feel the same way. Lawsuits filed against Xarelto federally now number around 1,800 cases. They have been consolidated to form multidistrict litigation number 2592 in the Eastern District of Louisiana, and will be overseen by Judge Eldon Fallon.
Contact BloodThinnerHelp.com: Joseph Osborne, 866-425-8902, Boca Raton, FL